Chlordiazepoxide hydrochloride

N05BA02(WHO) AU:S4(Prescription only)BR:Class B1(Psychoactive drugs)CA:Schedule IVDE: Prescription only (Anlage IIIfor higher doses)UK:Class CUS:Schedule IV 7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine-4-oxide 58-25-3Y 2712 3370 DB00475Y 10248513Y 6RZ6XEZ3CR D00267Y CHEBI:3611Y ChEMBL451Y DTXSID4046022 Interactive image ClC1=CC2=C(N=C(NC)C[N+]([O-])=C2C3=CC=CC=C3)C=C1 InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9H,10H2,1H3,(H,18,19)YKey:ANTSCNMPPGJYLG-UHFFFAOYSA-NY Chlordiazepoxide hydrochloride, sold under the brand nameLibrium, is asedativeandhypnoticmedication of thebenzodiazepineclass. It is used to treatanxiety,insomnia, and symptoms ofwithdrawalfromalcohol,benzodiazepines, and other drugs. It is also used to discontinue long-term use of other, shorter-acting benzodiazepines due to its long half-life. Chlordiazepoxide has a medium to longhalf-life, while itsactive metabolitehas a very long half-life. The drug hasamnesic,anticonvulsant,anxiolytic,hypnotic,sedative, andskeletal muscle relaxantproperties. Chlordiazepoxide was patented in 1958 and approved for medical use in 1960.It was the first benzodiazepine to be synthesized, and the discovery of chlordiazepoxide was by pure chance.Chlordiazepoxide and other benzodiazepines were initially accepted with widespread public approval, but were followed with widespread public disapproval and recommendations for more restrictive medical guidelines for its use.